India, July 7 -- Shares of Tvardi Therapeutics, Inc. (TVRD) are climbing around 42 percent on Tuesday morning after the company announced results from its Phase 1 study of TTI-109, its next-generation STAT3 inhibitor, showing improved tolerability and target engagement.
The company's shares are currently trading at $2.885 on the Nasdaq, up 42.04 percent. The stock opened at $2.16 and has climbed as high as $3.01 so far in today's session. Over the past year, it has traded in a range of $1.5 to $43.65.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....